2019-05-08
Discussions on a merger between NextCell AB and Idogen AB are suspended
The discussions that took place between the boards of NextCell Pharma AB ("NextCell") and Idogen AB ("Idogen") (together "The Companies"), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded that both companies will benefit from continuing to pursue their own activities.
Even though the discussions regarding a possible merger have now been suspended, the companies choose to continue discussions on how the companies could further cooperate in the future.
"We saw it as commercially logica
The discussions that took place between the boards of NextCell Pharma AB ("NextCell") and Idogen AB ("Idogen") (together "The Companies"), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded tha...
Read moreRead more2019-05-06
Update regarding possible merger between NextCell Pharma AB and Idogen AB
Discussions between the boards of NextCell Pharma AB (publ) ("NextCell") and Idogen AB (publ) ("Idogen") (together "The companies") regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019.
The companies have initiated a limited customary, legal, financial and technical/scientific due diligence. At the same time, discussions are taking place between the boards of the Companies. Additionally, the merger if implemented, will take place through an exchange offer from NextCell with consideration in
Discussions between the boards of NextCell Pharma AB (publ) ("NextCell") and Idogen AB (publ) ("Idogen") (together "The companies") regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019.
The companies h...
Read moreRead more2019-04-30
Half-year report
First Half (2018-09-01 till 2018-02-28)
· Operating income amounted to SEK 508,7795 (391,204).
· Operating result amounted to SEK -8,929,084 (-7,524,256).
· Earnings per share* amounted to SEK -0.83 (-0.88).
· Cash and bank amounted to SEK 6,886,879 (9,444,381).
· Solidity** amounted to 87 (59) %.
**Result per share: operating results divided by the average number of shares. Average number of shares for the first half of 2018/2019: 11,486,456 shares (8,505,425). Number of shares in NextCell as per February 28th, 11,486,456 shares
(8,505,425).
*
First Half (2018-09-01 till 2018-02-28)
· Operating income amounted to SEK 508,7795 (391,204).
· Operating result amounted to SEK -8,929,084 (-7,524,256).
· Earnings per share* amounted to SEK -0.83 (-0.88).
· Cash and bank amounted to SEK 6,886,879 (9,444,381).
...
Read moreRead more2019-04-26
NextCell Pharma AB comments on the trading halt of 25 April 2019
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt.
Discussions are currently underway between the boards of NextCell Pharma AB and Idogen AB regarding a potential merger. The structure being discussed would entail that NextCell Pharma AB makes a bid for all of the shares in Idogen AB and in turn will offer its own shares as a means of payment. At the time of the press release, the dialogue between the companies has only
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt.
Discussions are currently underway between the boards of NextCell Pharma ...
Read moreRead more2019-04-05
NextCell's biobank Cellaviva has received permission from IVO to handle stem cells from adipose tissue
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adults.
The company has previously been authorized by IVO to operate a tissue establishment using cells from the umbilical-cord and umbilical-cord-blood from newborns and operates a biobank for family saving of these cells. The extended approval state of fat-derived stem cells means for the fat-derived
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adu...
Read moreRead more2019-03-29
NextCell and Cellaviva are highlighted by KI Innovations
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social benefits that research of KI has contributed during the past 20 years.
Cellaviva was founded by researchers at Karolinska Institutet with help from Karolinska Institutet Innovations AB. The company became the first private stem cell bank in
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a fur...
Read moreRead more2019-03-22
NextCell continuous to strengthen development and collaborative activities
NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations.
NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project, both funded by Vinnova. The work conducted in the projects is a collaborative effort between different types of stakeholders, such as SMEs, big pharma and county councils, all with the common goal of improving the Swedish conditions for innovative cell therapies.
The latest development is that
NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations.
NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project...
Read moreRead more2019-02-22
NextCell continues to develop
NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's customer inflow has been increasing.
ProTrans-1, NXTCL's ongoing clinical trial for the treatment of type-1 diabetes, is divided into two parts, the first being a three-step dose escalation with three patients in each step, a
NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An applicat...
Read moreRead more